1072
J. Am. Chem. Soc. 1998, 120, 1072-1073
cysteine residues. Thus, new cysteines can be easily introduced
into the cavity, and hence, a number of cysteine mutants of IFABP
have been prepared.7 The mutant V60C was particularly interest-
ing to us because it allowed the pyridoxamine moiety to be
introduced deeper in the cavity than was possible with ALBP.8
This region of the protein is rich in aromatic residues including
one tryptophan, three tyrosines, and one phenylalanine as well
as two arginines.9 Modeling experiments suggested that these
residues might form specific contacts with keto acid or amino
acid substrates.
IFABP-PX60 (1, a construct incorporating a pyridoxamine
moiety at poition 60 of IFABP-V60C) was prepared in a similar
manner as previously described for ALBP-PX.5a Following
characterization of the conjugate, the rate of reductive amination
reactions using IFABP-PX60 (50 µM) and R-keto glutarate (3,
50 mM) was studied under single turnover conditions at pH 7.5
and 37 °C; this transformation is shown below.10 Initial results
Catalytic Enantioselective Reductive Amination in a
Host-Guest System Based on a Protein Cavity
Hao Kuang and Mark D. Distefano*
Department of Chemistry, UniVersity of Minnesota
Minneapolis, Minnesota 55455
ReceiVed August 8, 1997
Enzymes are highly efficient catalysts. As a result, many
strategies have been employed to design systems that possess
similar properties.1 Proteins are attractive scaffolds for the design
of new catalysts because their size allows the formation of a large
number of interactions between substrate and catalyst.2 Addition-
ally, recombinant DNA methods allow protein-based catalysts to
be modified in a facile manner either by site-directed mutagenesis
or by selection approaches.3 Fatty acid binding proteins are a
structurally unique family of proteins composed of two orthogonal
â-sheets and a R-helical region.4 These secondary structural
elements fold into a tertiary structure that forms a 600 Å3 cavity
which completely sequesters the fatty acids bound within. In
earlier work, we described the preparation of ALBP-PX, a
construct based on adipocyte lipid binding protein that contained
a pyridoxamine cofactor covalently attached to a cysteine residue
within the cavity.5 This conjugate reductively aminated several
R-keto acids to R-amino acids under single turnover conditions
with excellent enantioselectivities in some cases. However, these
reactions proceeded at rates comparable to those utilizing free
pyridoxamine indicating that the protein scaffold was involved
only in controlling reaction selectivity. To improve this system,
we decided to attach the pyridoxamine moiety to different
positions within the cavity in order to juxtapose the cofactor with
arrays of functional groups present elsewhere within the cavity.
Here, we describe the properties of IFABP-PX60, a catalyst based
on a mutant form of intestinal fatty acid binding protein (IFABP),
a protein structurally related to ALBP.6 This new conjugate
reductively aminates R-keto glutarate to glutamic acid with a
catalytic efficiency at least 200-fold greater than that of free
pyridoxamine. The reaction is catalytic and enantioselective; as
many as 50 turnovers with an enantiomeric purity of 95% ee
(enantiomeric excess) have been obtained.
after 24 h of reaction showed the formation of 1 equiv of glutamic
acid (4) indicating that the reaction was complete; this was quite
different from results obtained in similar experiments performed
with ALBP-PX in which only 46% conversion was observed after
24 h. Clearly, the new conjugate reacts at a more rapid rate.11
The kinetics of this reaction were next analyzed for both the
IFABP-PX60 protein as well as for free pyridoxamine (2). The
results of these experiments are shown in Figure 1. Analysis of
these data using a first-order kinetic model gave a kobsd of 0.18
h-1 for the protein and 0.0029 h-1 for pyridoxamine indicating a
62-fold increase in rate for IFABP-PX60 relative to the free
coenzyme under the same conditions. It should be noted that,
under these single turnover conditions, IFABP-PX60 produced a
68% ee of L-glutamic acid.
In view of the rapid rate obtained under single turnover
conditions, we next examined the ability of the conjugate to
perform this reaction under catalytic conditions in which the
pyridoxamine cofactor is regenerated by the addition of a second
amino acid that serves as an amine source as shown below. The
In our earlier work with ALBP-PX, Cys117 was used as the
site of pyridoxamine attachment. This residue is located near
the C-terminus of the protein and is proximal to the region where
the carboxylate group of the fatty acid ligand binds. To explore
other regions of the protein cavity, we focused on a different fatty
acid binding protein, IFABP, that, unlike ALBP, contains no
(1) Schultz, P. G. Science 1988, 240, 426.
(2) (a) Kaiser, E. T.; Lawrence, D. S. Science 1984, 226, 505. (b) Levine,
H. L.; Nakagawa, Y.; Kaiser, E. T. Biochem. Biophys. Res. Commun. 1977,
76, 64. (c) Corey, D. R.; Schultz, P. G. Science 1987, 238, 1401. (d) Polgar,
L.; Bender, M. L. J. Am. Chem. Soc. 1966, 88, 3153. (e) Neet, K. E.; Koshland,
D. E. Proc. Natl. Acad. Sci. U.S.A. 1966, 56, 1606. (f) Wu, Z. P.; Hilvert, D.
J. Am. Chem. Soc. 1989, 111, 4513. (g) Planas, A.; Kirsch, J. F. Biochemistry
1991, 30, 8268. (h) Wuttke, D. S.; Gray, H. B.; Fisher, S. L.; Imperiali, B. J.
Am. Chem. Soc. 1993, 115, 8455. (i) Imperiali, B.; Roy, R. S. J. Am. Chem.
Soc. 1994, 116, 12083. (j) Suckling, C. J.; Zhu, L. M. Bioorg. Med. Chem.
Lett. 1993, 3, 531. (k) Germanas, J. P.; Kaiser, E. T. Biopolymers 1990, 29,
39. (l) Bell, I. M.; Hilvert, D. New Biocatalysts Via Chemical Modification;
Bell, I. M., Hilvert, D., Eds.; John Wiley & Sons Ltd.: Chichester, 1994; p
73.
(7) Jiang, N.; Frieden, C. Biochemistry 1993, 32, 11015. (b) Frieden, C.;
Jiang, N.; Cistola, D. P. Biochemistry 1995, 34, 2724.
(8) Kuang, H.; Davies, R. R.; Distefano, M. D. Bioorg. Med. Chem. Lett.
1997, 7, 2055.
(9) Sacchettini, J. C.; Gordon, J. I.; Banaszak, L. J. J. Mol. Biol. 1989,
208, 327-339.
(10) For HPLC analysis methods, see: (a) Nimura, N.; Kinoshita, T. J.
Chromatogr. 1986, 352, 169. (b) Buck, R. H.; Krummen, K. J. Chromatogr.
1987, 387, 255. (c) Koh, J. T.; Breslow, R. J. Am. Chem. Soc. 1994, 116,
11234.
(11) Incubation of IFABP-V60C under similar conditions produced no
glutamate product. Addition of 1.0 mM EDTA has no effect on the rate of
reaction with IFABP-PX60 suggesting that rate enhancement via metal ion
catalysis is not occurring. Addition of equimolar Cu(II), Ni(II), or Zn(II)
actually reduces the rate and ee (although these ions accelerate reactions
containing free pyridoxamine).
(3) (a) Knowles, J. R. Science 1987, 236, 1252-1256. (b) Devlin, J. J.;
Panganiban, L. C.; Devlin, P. E. Science 1990, 249, 404-406.
(4) Banaszak, L.; Winter, N.; Xu, Z.; Bernlohr, D. A.; Cowan, S.; Jones,
T. A. AdV. Protein Chem. 1994, 45, 89.
(5) (a) Kuang, H.; Brown, M. L.; Davies, R. R.; Young, E. C.; Distefano,
M. D. J. Am. Chem. Soc. 1996, 118, 10702. (b) Davies, R. R.; Distefano, M.
D. J. Am. Chem. Soc. 1997, 119, 11643.
(6) Lowe, J. B.; Sacchettini, J. C.; Laposata, M.; McQuillan, J. J.; Gordon,
J. I. J. Biol. Chem. 1987, 262, 5931.
S0002-7863(97)02771-6 CCC: $15.00 © 1998 American Chemical Society
Published on Web 01/22/1998